Physical Activity Directly Before Immunotherapy (Nivolumab and Ipilimumab) in Melanoma

Inclusion Criteria: * Histologically confirmed metastatic malignant melanoma with an indication for immunotherapy (Nivolumab and Ipilimumab). * The participant provides written informed consent for the study. * The participant is at least 18 years of age on the day the informed consent is signed. * No prior systemic anticancer therapy for metastatic disease (e.g., cytotoxic or targeted agents). * ECOG (Eastern Cooperative Oncology Group) performance status score of ≤ 2. * No physical impairment that would preclude participation in physical exercise. Exclusion Criteria: * Major surgery within 2 weeks prior to the start of the study intervention, or participants who have not fully recovered from the effects of a previous surgery. * Participants with a diagnosed immunodeficiency, or those receiving chronic systemic corticosteroid therapy (at a dose greater than 10 mg prednisone equivalent per day), or any other form of immunosuppressive therapy within 7 days prior to the first dose of the study medication. * Participants with an active infection requiring systemic therapy. * Participants with a known history of infection with human immunodeficiency virus (HIV) or hepatitis.